FDA Panel Recommends Moderna's mRNA Flu Vaccine for Older Adults

An FDA advisory committee has unanimously endorsed Moderna's mRNA-based influenza vaccine, mFlusiva, for individuals aged 50 and above. This recommendation follows robust Phase 3 clinical trial data demonstrating the vaccine's efficacy and potential advantages over traditional flu shots. The mRNA platform could offer a more durable immune response, broader strain coverage, and faster production capabilities.